Follow the オンコリスバイオファーマ株式会社 stock price and the full management transaction log of the company, a publicly traded company based in Japan. Shares trade on JP JP, under the supervision of EDINET (Japan FSA). Market capitalisation: €83.7bn. The latest transaction was disclosed on 5 February 2026 (Holding update). Among the most active insiders: SMBC Nikko Securities Inc.. The full history is openly available.
31
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
17Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 17,812 of 25,484 companies
38.6
score / 100
Value
27
Quality
51
FCF yld-2.3%
Earn yld-2.5%
EV/EBITDA·
ROE-110%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Oncolis BioPharma Inc. is a Japanese biopharmaceutical company focused on developing innovative cancer treatments. It specializes in the research and commercialization of therapies based on oncolytic viruses.